Certolizumab pegol in the treatment of Crohn’s disease: evidence from the PRECiSE clinical trial program

2011 ◽  
Vol 1 (3) ◽  
pp. 459-465
Author(s):  
Ian C Lawrance
Keyword(s):  
Clinical Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Clinical Trial Program

scholarly journals Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study

2010 ◽  
Vol 33 (2) ◽  
pp. 185-193 ◽  
Author(s):  
S. Schreiber ◽  
I. C. Lawrance ◽  
O. Ø. Thomsen ◽  
S. B. Hanauer ◽  
R. Bloomfield ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Randomised Clinical Trial ◽  
Controlled Study

scholarly journals Certolizumab pegol for the treatment of Crohn’s disease

2011 ◽  
Vol 4 (6) ◽  
pp. 375-389 ◽  
Author(s):  
Stefan Schreiber
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Fixed Dose ◽  
Sustained Remission ◽  
Early Therapy ◽  
Rapid Induction ◽  
Clinical Trial Program

In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn’s disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate to severe CD. Certolizumab pegol is an effective and well-tolerated therapy both in patients who have already received biologics and in patients who are anti-TNF naïve. Benefits of therapy include a stable dosing regimen, which allows for rapid induction of a clinical response followed by long-term maintenance of response and remission under one fixed dose. Treatment with certolizumab pegol has been shown to improve function and quality of life in patients with CD, and insights into the potential mechanisms by which certolizumab pegol effects a response in CD suggest that this agent may have the potential to slow or even modify disease progression. Early therapy is particularly effective and could help control CD progression and lessen the burden of disease on patients.

scholarly journals Creatine Supplementation for Patients with Inflammatory Bowl Diseases: A Scientific Rationale for a Clinical Trial

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1429
Author(s):  
Theo Wallimann ◽  
Caroline H. T. Hall ◽  
Sean P. Colgan ◽  
Louise E. Glover
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Crohn’S Disease ◽  
Pilot Study ◽  
Crohn's Disease ◽  
Single Case ◽  
Initial Period ◽  
Creatine Supplementation

Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that “oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular energy precursor, is likely to be effective in inducing a favorable response and/or remission in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and/or Crohn’s disease”. A current pilot clinical trial that incorporates the use of oral Cr at a dose of 2 × 7 g per day, over an initial period of 2 months in conjunction with ongoing therapies (NCT02463305) will be informative for the proposed larger, more long-term Cr supplementation study of 2 × 3–5 g of Cr per day for a time of 3–6 months. This strategy should be insightful to the potential for Cr in reducing or alleviating the symptoms of IBD. Supplementation with chemically pure Cr, a natural nutritional supplement, is well tolerated not only by healthy subjects, but also by patients with diverse neuromuscular diseases. If the outcome of such a clinical pilot study with Cr as monotherapy or in conjunction with metformin were positive, oral Cr supplementation could then be used in the future as potentially useful adjuvant therapeutic intervention for patients with IBD, preferably together with standard medication used for treating patients with chronic ulcerative colitis and/or Crohn’s disease.

T1129 Predictors of Response in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Multiple Regression Analysis of PRECISE 2 Data

2008 ◽  
Vol 134 (4) ◽  
pp. A-489-A-490 ◽  
Author(s):  
Stephen B. Hanauer ◽  
Stefan Schreiber ◽  
Ole O. Thomsen ◽  
Gary R. Lichtenstein ◽  
Ralph Bloomfield ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Multiple Regression Analysis ◽  
Multiple Regression ◽  
Certolizumab Pegol ◽  
Predictors Of Response

S1058 Certolizumab Pegol Improves Health-Related Quality of Life in Crohn's Disease Patients for Whom Infliximab Treatment Was Not Successful: Results from the WELCOME Study

2009 ◽  
Vol 136 (5) ◽  
pp. A-179 ◽  
Author(s):  
Brian G. Feagan ◽  
William J. Sandborn ◽  
Douglas C. Wolf ◽  
Krassimir Mitchev ◽  
Corinne Jamoul ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Infliximab Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document